…
CM-Path Year Two Report (PDF)
'This report demonstrates the highlights of Year Two of the CM-Path Programme. We have already delivered a great deal but much remains to be done and there is still an urgent need for the CM-Path initiative, at full strength.…
Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington
'It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux (2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects.…
Proton Beam Therapy – the Challenges of Delivering High-quality Evidence of Clinical Benefit
'The use of proton beam therapy (PBT) offers the opportunity to improve greater conformality of radiotherapy treatment delivery in some patients.…
Latest radiotherapy news from NCRI
'CTRad moving into new phase of funding and welcoming new members CTRad has now embarked on its fourth phase of…
Evaluating excellence in radiotherapy research: the UK CTRad ‘Centres of Excellence’ initiative
'Establishing internationally accepted criteria for assessing the quality of multidisciplinary radiotherapy research programmes would be of value to centres,
research funders, patients and other stakeholders.…
Consensus statement on the role of Pathologists in ctDNA here (PDF)
'This document follows on from the findings of the CM-Path “The Liquid Biopsy: ctDNA, Circulating Tumour Cells and Bloodborne Biomarkers” workshop on the 8th March 2018 at the Royal Society of Medicine with emphasis on the role of cellular pathologists in supporting the implementation of innovative technologies into diagnostic pathways across the NHS. …
The Liquid Biopsy Biomarker Workshop (PDF)
'This was the second in a series of biomarker workshops organised by CM-Path’s Discovery Workstream, where invited speakers gave an overview on circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) and discussed recent advances in technology, which have led to their application both in research and more recently, in clinical trials. During very lively panel discussion sessions, the barriers to widespread adoption within clinical practise was discussed.…
NCRI Annual Review 2016-17
'A review of NCRI’s key activities and accounts for the financial year 2016/17…
Overcoming Barriers to Molecular Diagnostics and Digital Pathology Uptake
'To advance research in pathology, providing scope for wider and faster implementation of novel technology for patients’ benefit, CM-Path recognises the value of collaborating with industry, regulators and others. …
Awareness among Pathologists of NCRI CSGs (PDF)
'This was the second in a series of biomarker workshops organised by CM-Path’s Discovery Workstream, where invited speakers gave an overview on circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) and discussed recent advances in technology, which have led to their application both in research and more recently, in clinical trials. During very lively panel discussion sessions, the barriers to widespread adoption within clinical practise was discussed.…
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy
'Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. …